Table 1.
Descriptive Characteristics at Study Entry for People With Recent Injection Drug Use or Receiving Opioid Agonist Treatment Recruited and Followed in SIMPLIFY and D3FEAT
| Variable | Total (N = 190) |
SIMPLIFY (n = 103) |
D3FEAT (n = 87) |
|---|---|---|---|
| Age, mean (standard deviation), y | 47 (9) | 47 (9) | 47 (10) |
| Male sex | 141 (74%) | 74 (72%) | 67 (78%) |
| Completed high school education | 92 (49%) | 50 (49%) | 42 (49%) |
| Unstable housing, past 6 months | 33 (18%) | 23 (22%) | 10 (12%) |
| Any injection drug use, past month | 117 (62%) | 77 (75%) | 40 (47%) |
| Opioid injection, past month | 88 (47%) | 58 (56%) | 30 (35%) |
| Stimulant injection, past month | 58 (39%) | 39 (39%) | 19 (23%) |
| Noninjecting opioid use, past month | 42 (23%) | 26 (26%) | 16 (19%) |
| Noninjecting stimulant use, past month | 48 (26%) | 28 (28%) | 20 (24%) |
| Sharing of injection equipment, past month | 28 (16%) | 22 (22%) | 6 (8%) |
| Currently receives opioid agonist treatment | 114 (61%) | 53 (52%) | 61 (72%) |
| Alcohol use score,a median (interquartile range) | 2 (0–4) | 2 (0–4) | 1 (0–4) |
| ≥Advanced fibrosisb | 32 (18%) | 18 (19%) | 14 (16%) |
Except for age and gender, data were unavailable for 2 participants recruited in D3FEAT. Missing values are reflected in the frequency distributions for each variable.
a Measured using the Alcohol Use Disorders Identification Test–Consumption.
bAdvanced fibrosis was defined as having a METAVIR score of F3 or higher.